Methionine and Cysteine Restriction in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03629392

Recruitment Status : Completed

First Posted : August 14, 2018

Last Update Posted : March 25, 2020

Sponsor:

Collaborators:

The Research Council of Norway

University of Oxford

Information provided by (Responsible Party):

Kathrine Vinknes, University of Oslo

Study Description

Brief Summary:

The aim of this study is to examine the effect of methionine and cysteine restriction on energy and macronutrient metabolism in overweight human subjects

Condition or disease	Intervention/treatment	Phase
Overweight	Behavioral: Low met/cys diet Behavioral: Moderate met/cys diet Behavioral: High met/cys diet	Not Applicable

Detailed Description:

The sulfur-containing amino acid methionine and its downstream metabolite cysteine has been associated with fat mass in animal studies and human observational studies. Some of the proposed mechanisms include an association with lipogenesis, insulin sensitivity and disrupted energy metabolism.

The overall aim of this project is to evaluate the effects of a diet low in methionine and cysteine on markers of lipids, amino acids, glucose and other biomarkers related to energy metabolism, including transcriptomic and protein expression data from adipose tissue and lymphocytes. Overweight and obese but otherwise healthy volunteers will be randomized to receive a diet either low, moderate or high in methionine and cysteine concentrations for 1 week.

This is a pilot study that may be considered an extension of NCT02647970. In addition to the primary and secondary outcomes we will evaluate the feasibility of the intervention and procedures.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	19 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Masking Description:	Participant: The diets are similar except for methionine and cysteine, and it is thought that the participants will not be able to identify their treatment allocation by taste. Investigator: Randomization will be carried out by an investigator that is not related to the study. All foods will be pre-packaged and delivered to the participants by an unrelated company.
Primary Purpose:	Basic Science
Official Title:	Dietary Methionine and Cysteine Restriction in Overweight Human Subjects
Actual Study Start Date :	October 8, 2018
Actual Primary Completion Date :	December 11, 2018
Actual Study Completion Date :	December 11, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Cysteine Racemethionine Methionine Cysteine hydrochloride

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Low met/cys diet Dietary intervention	Behavioral: Low met/cys diet Dietary intervention with low contents of methionine and cysteine
Experimental: Moderate met/cys diet Dietary intervention	Behavioral: Moderate met/cys diet Dietary intervention with moderate contents of methionine and cysteine
Active Comparator: High met/cys diet Dietary intervention	Behavioral: High met/cys diet Dietary intervention with high contents of methionine and cysteine

Outcome Measures

Primary Outcome Measures :

Change in plasma concentrations of amino acids [ Time Frame: Baseline, Day 1, Day 3 and Day 7 (final visit) ]
Measurement of biomarkers of amino acid metabolism, including plasma concentrations of methionine, cysteine and related metabolites
Change in protein expression activity in tissues [ Time Frame: Baseline and day 7 (final visit for adipose tissue, Baseline and day 1, 3 and 7 (final visit) for lymphocytes. ]
Measurement of protein expression and activity related to methionine and cysteine metabolism in adipose tissue and lymphocytes.

Secondary Outcome Measures :

Change in plasma concentrations of fatty acids [ Time Frame: Baseline, Day 1, Day 3 and Day 7 (final visit) ]
Measurement of fatty acid content in plasma
Change in plasma activity indices of steaoryl-CoA desaturase [ Time Frame: Baseline, Day 1, Day 3 and Day 7 (final visit) ]
Calculated based onthe ratio of plasma concentrations of products and precursors
Change in protein expression of steaoryl CoA-desaturase in adipose tissue [ Time Frame: Baseline and Day 7 (final visit) ]
Measurement of protein expression of steaoryl CoA-desaturase in adipose tissue
Change in protein expression of steaoryl CoA-desaturase in lymphocytes [ Time Frame: Baseline, Day 1, Day 3 and Day 7 (final visit) ]
Measurement of protein expression of steaoryl CoA-desaturase in lymphocytes
Change in steaoryl CoA-desaturase activity in adipose tissue [ Time Frame: Baseline and Day 7 (final visit) ]
Measurement of enzyme activity of steaoryl CoA-desaturase in adipose tissue
Diet feasibility [ Time Frame: Baseline, Day 1, Day 3 and Day 7 (final visit) ]
Diet feasibility will be measured by a self-administered questionnaire
Diet compliance [ Time Frame: Baseline, Day 1, Day 3 and Day 7 (final visit) ]
Compliance with the diet will be measured by a self-administered questionnaire
Body composition [ Time Frame: Baseline and day 7 (final visit) ]
Measurement of body composition by bioimpedance and dual X-ray absorptometry

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	20 Years to 40 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Body mass index of 25-35 kg/m2

Exclusion Criteria:

High physical activity
Smoking
Drugs
Chronic disease
Pregnancy or breastfeeding

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03629392

Locations

Layout table for location information

Norway
University of Oslo
Oslo, Norway, 0372

Sponsors and Collaborators

University of Oslo

The Research Council of Norway

University of Oxford

More Information

Publications of Results:

Olsen T, Øvrebø B, Haj-Yasein N, Lee S, Svendsen K, Hjorth M, Bastani NE, Norheim F, Drevon CA, Refsum H, Vinknes KJ. Effects of dietary methionine and cysteine restriction on plasma biomarkers, serum fibroblast growth factor 21, and adipose tissue gene expression in women with overweight or obesity: a double-blind randomized controlled pilot study. J Transl Med. 2020 Mar 11;18(1):122. doi: 10.1186/s12967-020-02288-x.

Layout table for additonal information

Responsible Party:	Kathrine Vinknes, Kathrine Vinknes, PhD, University of Oslo
ClinicalTrials.gov Identifier:	NCT03629392
Other Study ID Numbers:	239948-B
First Posted:	August 14, 2018 Key Record Dates
Last Update Posted:	March 25, 2020
Last Verified:	March 2020

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Kathrine Vinknes, University of Oslo:


Methionine Cysteine Energy metabolism Sulfur amino acids

Additional relevant MeSH terms:

Layout table for MeSH terms

Overweight Body Weight

To Top